Interleukin-2 (IL-2), Interleukin-5 (IL-5) and Interleukin-17 (IL-17) Levels of Patients With Stainless Steel Crowns

Completed

Brief Summary: The aim of this study is to investigate whether nickel hypersensitivity following stainless steel crown treatment in children aged 3-9 leads to an increase in IL-2, IL-5, and IL-17 levels by analyzing saliva samples. By doing so, the study seeks to prevent potential hypersensitivity reactions after stainless steel crown treatment.

The main question it aims to answer is:

Which interleukin level increases in the controls 1 week after stainless steel crowns are applied? Researchers will investigate whether there is a significant increase in interleukin levels in children's saliva before and after the procedure.

Participants will:

They will provide saliva samples before stainless steel crowns are applied They will visit the clinic after 1 week for check-ups and tests.

Detailed Description: Expression levels of IL-2, IL-5 and IL-17 in the saliva of individuals aged 3-9 years who underwent stainless steel crown will be recorded before and after the procedure. Before the saliva sample collection procedure, the patient will be asked to rinse their mouth with sterile water and then spit into sterile plastic cups. After collecting approximately 5 ml of saliva, the saliva will be transferred to appropriate eppendorfs and stored at -40 degrees Celsius. For the second post-procedure, the same algorithms will be applied for saliva collection seven days after the crown procedure. Also ph value and ion levels of saliva will be measured.

Recruitment & Eligibility

Inclusion Criteria

Patients with teeth requiring stainless steel crowns due to having caries on two or more surfaces.
Pediatric patients between 3-9 years old

Exclusion Criteria

Patients having any dental materials, such as fillings, fissure sealants, root canal treatments, or space maintainers
Patients with known allergies to various foods and materials.
Patients with systemic diseases that affect the immune system.
Patients with a history of chemotherapy or radiotherapy.

Primary Outcome Measures

Name	Time	Method
IL-2, IL-5, IL-17 Expression Level (Fold Change)	Sample collection at baseline (Day 0) and 7 days after treatment	Relative gene expression analysis was performed using quantitative PCR (qPCR) with appropriate primers. The results were reported as fold change relative to baseline values.

Secondary Outcome Measures